[Pathogenesis and progression of neuropathies in diabetic patients with endothelial dysfunction].
Naruse
Keiko
K
Department of Internal Medicine, Aichi-Gakuin University School of Dentistry.
Nakamura
Jiro
J
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D002096:C-Peptide / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000209:etiology*; D018450:Disease Progression; D015195:Drug Design; D004730:Endothelium, Vascular / Q000166:cytology / Q000503:physiopathology*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000502:physiology; D052250:Nitric Oxide Synthase Type III; D010525:Peripheral Nerves / Q000098:blood supply; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology; D064546:Protein Kinase C beta; D008063:Thioctic Acid / Q000627:therapeutic use; D014664:Vasodilation
D000975:Antioxidants; D002096:C-Peptide; D009569:Nitric Oxide; D008063:Thioctic Acid; D000449:Aldehyde Reductase; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D011493:Protein Kinase C; D064546:Protein Kinase C beta